Dexasone
T-Cell Large Granular Lymphocyte Leukemia
Explore 7 assets in T-Cell Large Granular Lymphocyte Leukemia →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01129180CT.gov Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | — | Completed | — | — | — |
NCT01088763CT.gov Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell Large Granular Lymphocyte Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Fred Hutchinson Cancer Center | P2 | B · 60 |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Cyclosporin A | Case Comprehensive Cancer Center | P2 | BB |
| Cyclophosphamide | Case Comprehensive Cancer Center | P2 | BB |
| Busulfanum | Ohio State University Comprehensive Cancer Center | P2 | BB |
| Rituximab | Northwestern University | P2 | B |
| Cediranib | Morphotek | P2 | B |
| Tacrolimus | University of Medicine and Dentistry of New Jersey | P2 | B |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Ohio State University Comprehensive Cancer Center | P2 | B |
+39 more in the T-Cell Large Granular Lymphocyte Leukemia cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in T-Cell Large Granular Lymphocyte Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-t-cell-large-granular-lymphocyte-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →